1
Centre Léon Bérard, Service d’Hématologie Clinique, 69008 Lyon, France
2
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire de Biochimie et Biologie moléculaire, 69495 Pierre-Bénite CEDEX, France
3
Cancer Research Center of Lyon, INSERM U1052 UMR CNRS 5286, Equipe labellisée LIGUE Contre le Cancer, 69008 Lyon, France
4
Université de Lyon, Université Lyon 1, Faculté de Médecine et de Maïeutique Lyon Sud Charles Mérieux, 69921 Oullins CEDEX, France
5
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d’Hématologie, 69495 Pierre-Bénite CEDEX, France
6
Hospices Civils de Lyon, Service de Biostatistique—bioinformatique et plateforme de séquençage haut débit NGS-CHU Lyon, 69677 Bron CEDEX, France
7
Université de Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Evolutive UMR5558, équipe biostatistique-santé, F-69424 Lyon, France
8
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d’Hématologie Clinique, 69495 Pierre-Bénite CEDEX, France
9
Université de Lyon, Université Lyon 1, Faculté de Pharmacie Rockefeller, 69373 Lyon CEDEX, France
Abstract
High throughput sequencing (HTS) is increasingly important in determining cancer diagnoses, with subsequent prognostic and therapeutic implications. The biology of cancer is becoming increasingly deciphered and it is clear that therapy needs to be individually tailored. Whilst translational research plays an important role
[...] Read more.
High throughput sequencing (HTS) is increasingly important in determining cancer diagnoses, with subsequent prognostic and therapeutic implications. The biology of cancer is becoming increasingly deciphered and it is clear that therapy needs to be individually tailored. Whilst translational research plays an important role in lymphoid malignancies, few guidelines exist to guide biologists and routine laboratories through this constantly evolving field. In this article, we review the challenges of interpreting HTS in lymphoid malignancies and provide a toolkit to interpret single nucleotide variants obtained from HTS. We define the pre-analytical issues such as sequencing DNA obtained from formalin-fixed and paraffin-embedded tissue (FFPE), the acquisition of germline DNA, or the bioinformatic pitfalls, the analytical issues encountered and how to manage them. We describe the main constitutional and cancer databases, their characteristics and limitations, with an emphasis on variant interpretation in lymphoid malignancies. Finally, we discuss the challenges of predictions that one can make using in silico or in vitro modelling, pharmacogenomic screening, and the limits of those prediction tools. This description of the current status in genomic interpretation highlights the need for new large databases and international collaboration in the lymphoma field.
Full article